Candriam S.C.A. Has $61.93 Million Stock Position in HCA Healthcare, Inc. $HCA

Candriam S.C.A. boosted its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 3.2% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 161,640 shares of the company’s stock after buying an additional 5,069 shares during the period. Candriam S.C.A.’s holdings in HCA Healthcare were worth $61,927,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. ORG Partners LLC boosted its position in HCA Healthcare by 27.9% during the second quarter. ORG Partners LLC now owns 142 shares of the company’s stock worth $55,000 after purchasing an additional 31 shares during the period. Avantax Advisory Services Inc. grew its stake in HCA Healthcare by 0.4% in the 1st quarter. Avantax Advisory Services Inc. now owns 8,077 shares of the company’s stock valued at $2,791,000 after buying an additional 32 shares during the last quarter. Glenview Trust co lifted its position in HCA Healthcare by 2.3% during the 1st quarter. Glenview Trust co now owns 1,451 shares of the company’s stock worth $501,000 after acquiring an additional 32 shares during the last quarter. Horizon Investments LLC raised its stake in HCA Healthcare by 1.1% during the 1st quarter. Horizon Investments LLC now owns 3,175 shares of the company’s stock valued at $1,097,000 after purchasing an additional 33 shares during the last quarter. Finally, Sivia Capital Partners LLC raised its position in shares of HCA Healthcare by 5.5% during the second quarter. Sivia Capital Partners LLC now owns 630 shares of the company’s stock valued at $241,000 after buying an additional 33 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Up 2.5%

Shares of HCA stock opened at $474.08 on Thursday. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $479.43. The firm has a market cap of $108.18 billion, a price-to-earnings ratio of 18.33, a PEG ratio of 1.38 and a beta of 1.41. The stock has a 50-day moving average price of $431.29 and a 200 day moving average price of $394.54.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, topping the consensus estimate of $5.64 by $1.32. The company had revenue of $19.16 billion during the quarter, compared to analysts’ expectations of $18.55 billion. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. HCA Healthcare’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. Sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.72 per share. The ex-dividend date is Monday, December 15th. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s dividend payout ratio (DPR) is 11.13%.

Insider Transactions at HCA Healthcare

In other news, EVP Michael R. Mcalevey sold 3,892 shares of HCA Healthcare stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the transaction, the executive vice president directly owned 3,487 shares of the company’s stock, valued at $1,652,105.73. This trade represents a 52.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael S. Cuffe sold 3,836 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president directly owned 31,503 shares of the company’s stock, valued at approximately $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HCA. The Goldman Sachs Group lifted their price objective on HCA Healthcare from $470.00 to $520.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of HCA Healthcare in a research report on Monday, October 27th. Stephens boosted their price target on shares of HCA Healthcare from $450.00 to $500.00 and gave the company an “overweight” rating in a research report on Monday, October 27th. Weiss Ratings reiterated a “buy (b-)” rating on shares of HCA Healthcare in a research note on Wednesday, October 8th. Finally, Mizuho boosted their price objective on HCA Healthcare from $475.00 to $505.00 and gave the stock an “outperform” rating in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, HCA Healthcare has an average rating of “Moderate Buy” and a consensus target price of $473.53.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.